Buscar resultados de ensayos clínicos
Primary Central Nervous System Lymphoma - 27 Studies Found
Estado | Estudiar |
Not yet recruiting |
Nombre del estudio: Ketogenic Diet Adjunctive to HD-MTX Chemotherapy for Primary Central Nervous System Lymphoma Condición: Primary Central Nervous System Lymphoma Fecha: 2016-11-29 Intervenciones:
|
Recruiting |
Nombre del estudio: MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma Condición: Primary Central Nervous System Lymphoma Fecha: 2015-03-01 Intervenciones: Drug: R-MT followed by auto-HSCT Four cycles of Induction therapy: Rituximab 375mg/m2 d1; Methotrexate 3 |
Recruiting |
Nombre del estudio: Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL) Condición: Primary Central Nervous System Lymphoma Fecha: 2016-05-17 Intervenciones: Drug: pembrolizumab Pembrolizumab 200 mg every 3 weeks |
Withdrawn |
Nombre del estudio: Antineoplaston Therapy in Treating Patients With Primary Central Nervous System Lymphoma Condición: Primary Central Nervous System Lymphoma Fecha: 1999-11-01 Intervenciones:
|
Withdrawn |
Nombre del estudio: a Phase II Study in Primary Central Nervous System Lymphoma Condición: Primary Central Nervous System Lymphoma Fecha: 2007-04-02 Intervenciones:
|
Recruiting |
Nombre del estudio: PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma Condición: Primary Central Nervous System Lymphoma Fecha: 2016-01-07 Intervenciones: Drug: PQR309 Oral PQR309, 80mg or 60mg daily or intermittent dosing |
Not yet recruiting |
Nombre del estudio: PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma Condición: Primary Central Nervous System Lymphoma Fecha: 2017-04-10 Intervenciones: Drug: PQR309 Oral PQR309, 80mg or 60mg daily or intermittent dosing |
Withdrawn |
Nombre del estudio: Study of Pemetrexed to Treat Recurrent or Progressive Primary Central Nervous System Lymphoma Condición: Primary Central Nervous System Lymphoma Fecha: 2008-07-03 Intervenciones: Drug: Pemetrexed 500 mg/m2 given as an injection into a vein over 10 minutes once every 21 days until pr |
Completed |
Nombre del estudio: Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma Condición: Primary Central Nervous System Lymphoma Fecha: 2005-09-13 Intervenciones:
|
Terminated |
Nombre del estudio: Neurotoxicity in Primary Central Nervous System Lymphoma (PCNSL): An International Observational Study of Cognition in Long Term Survivors Condición: Primary Central Nervous System Lymphoma (PCNSL) Fecha: 2008-07-02 |